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Background: Whether the TRN-SR2/HIV-1 IN 
interaction mediates the nuclear import of HIV 
is controversial. 
Results: The replication defective HIV integrase 
mutant INR263A/K264A displays a two-fold 
reduction in interaction with TRN-SR2 and PIC
nuclear import. 
Conclusion: The HIV-IN TRN-SR2 protein-
protein interaction is important for HIV nuclear 
import 
Significance: The IN/TRN-SR2 interaction 
interface is a potential target for future antiviral 
therapy.  
Abstract 
Transportin-SR2 (Tnpo3, TRN-SR2), a human 
karyopherin encoded by the TNPO3 gene, has 
been identified as a cellular cofactor of HIV-1
replication, specifically interacting with HIV-1
integrase (IN). Whether this interaction mediates 
the nuclear import of HIV remains controversial. 
We previously characterized the TRN-SR2 
binding interface in IN and introduced mutations 
at these positions to corroborate the biological 
relevance of the interaction. The pleiotropic 
nature of IN mutations complicated the 
interpretation. Indeed, all previously tested IN 
interaction mutants also affected reverse 
transcription (RT). Here we report on a virus 
with a pair of IN mutations, INR263A/K264A, that 
significantly reduce interaction with TRN-SR2. 
The virus retains wild-type reverse transcription 
activity but displays a block in nuclear import 
and integration, as measured by Q-PCR. The 
defect in integration of this mutant resulted in a 
smaller increase in the number of 2-LTR circles 
than for virus specifically blocked at integration 
by raltegravir or catalytic site mutations 
(IND64N/D116N/E152Q). Finally, using an eGFP-IN 
labeled HIV fluorescence-based import assay, 
the defect in nuclear import was corroborated. 
These data altogether underscore the importance 
of the HIV-IN TRN-SR2 protein-protein 
interaction for HIV nuclear import and validate 
the IN/TRN-SR2 interaction interface as a 
promising target for future antiviral therapy.  
Introduction 
Lentiviruses such as the human 
immunodeficiency virus type 1 (HIV-1) infect 
both dividing and non-dividing cells (1,2).
Following reverse transcription, the pre-
integration complex (PIC) composed of the viral 
DNA and a complex of viral and cellular 
proteins crosses the nuclear membrane via active 
nuclear import through the nucleopore (3).
Nuclear entry precedes provirus establishment 
through stable insertion of the viral DNA into 
the host chromatin as catalyzed by HIV-1
integrase (IN) and constitutes a genuine 
bottleneck during HIV replication (4). As such it 
represents an interesting, yet unexploited target 
for antiviral therapy. Despite extensive research,
the underlying mechanism of HIV nuclear 
import remains a contentious issue until today.
Several viral components, including capsid 
(CA), the central polypurine tract (cPPT), 
integrase (IN), matrix (MA) and viral protein R 
(Vpr) have been reported to play a role in 
nuclear import but no consensus has been 
reached (5-7). Nuclear import in the human cell 
is orchestrated by a plethora of karyopherins,
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comprising both broad-spectrum and highly 
specialized transporters. Several of these have 
been suggested to take part in HIV nuclear 
import, in particular importin-α/β (8-10), 
importin-α3 (11) and importin-7 (12-15). In 
2008, transportin-SR2 (TRN-SR2, transportin-3,
Tnpo3), encoded by the TNPO3 gene, was 
independently identified as a cellular cofactor of 
HIV in two genome-wide siRNA screens (16,17) 
and picked up as a specific binding partner of 
HIV IN (18). Using RNAi technology, the 
crucial role of TRN-SR2 in HIV replication was 
demonstrated (16-18).  
Although the importance of TRN-SR2 for HIV 
replication is widely accepted and has been 
independently confirmed by different research 
groups, the exact mechanism of action  remains 
unresolved (19-29). Because TRN-SR2 is a 
known karyopherin, involved in nuclear import 
of essential splicing factors, namely 
serine/arginine-rich proteins (SR proteins) and 
also certain non-SR proteins (30-33), it is a
plausible candidate import factor for HIV.  
IN catalyzes the insertion of the viral DNA into 
the host chromatin in two distinct steps. During 
3’-processing the enzyme removes the 3’-
terminal GT dinucleotide from both long 
terminal repeat (LTR) ends resulting in reactive 
3’-OH groups. This reaction is believed to occur 
in the cytoplasm. The processed cDNA is then 
imported in the nucleus where a nucleophilic 
attack of the exposed 3’-OH groups on the target 
DNA phophodiester backbone and 
transesterification result in stable insertion of the 
viral DNA into the host chromatin. During HIV 
infection a minute fraction of the proviral cDNA 
is subjected to 1- and 2-long terminal repeat 
(LTR) circle formation in the nucleus, which can 
be monitored by Q-PCR (34). IN catalytic site 
mutations or the addition of integrase inhibitors 
during HIV infection reproducibly result in 
abortive integration and a steep increase in 2-
LTR circles (34), whereas a decrease in 2-LTR 
circles is generally accepted to reflect a block in 
nuclear import (35). In line, a reduction in the 
number of 2-LTR circles was measured after 
RNAi-mediated TRN-SR2 depletion 
(18,20,21,36), suggesting a nuclear import 
defect. In a direct HIV nuclear import assay 
using IN-eGFP labeled PICs (18,37), we 
demonstrated a reduction of nuclear versus
cytoplasmic PICs after TRN-SR2 knockdown 
(18), underscoring a role for TRN-SR2 in HIV 
nuclear import. 
Although we and others have shown that TRN-
SR2 directly interacts with HIV IN 
(18,19,27,38,39), the mechanism of action  has 
been questioned (19,23,36,40,41). Especially 
reports on a set of HIV capsid mutations (e.g. 
N74D) that reduce the dependency of HIV 
replication on TRN-SR2 in single-round HIV 
infection assays, put forward an alternative 
hypothesis according to which TRN-SR2 exerts 
its role through direct interaction with the viral 
CA protein (19,23). However, in multiple round, 
spreading infection experiments, HIV carrying 
the N74D CA mutation remained sensitive to 
TRN-SR2 depletion (25). Possibly, these capsid 
mutations affect virus uncoating (25,42) and 
thus constitute a rate-limiting step prior to HIV 
nuclear import. Initially, the N74D capsid 
mutant was picked up as a resistance mutation 
against overexpression of a C-terminally 
truncated fragment of the mouse Cleavage and 
Polyadenylation Specificity Factor subunit 6
(mCPSF6-358) (43). CPSF6 is a cellular protein 
involved in splicing and polyadenylation of pre-
mRNA that carries an RS domain at its C-
terminus. Since CPSF6 binds HIV CA (40), it
has been suggested that TRN-SR2 depletion 
might result in cytoplasmic accumulation of 
CPSF6, which, in turn, might perturb viral 
uncoating through CPSF6–CA binding, leading 
to an indirect block in nuclear import and 
restricted HIV replication (36,40,41). Still, the 
cytoplasmic accumulation of CPSF6 after TRN-
SR2 knockdown is not always observed (36,41). 
In any case, the fact that a virus defective for 
interaction with CPSF6 (CAN74D) remains 
sensitive to TRN-SR2 knockdown in a multiple-
round replication experiment (25) suggests that 
cytoplasmic accumulation of CPSF6 is not a sole 
cause for the HIV replication deficit upon TRN-
SR2-depletion.
These indirect lines of evidence do not 
unequivocally address the question whether the 
IN/TRN-SR2 interaction mediates nuclear entry. 
To study its role in HIV nuclear import a 
specific block in the IN/TRN-SR2 interaction is 
required. To uncouple the effect of TRN-SR2 
knockdown from the possible cytoplasmic 
accumulation of CPSF6 or other cargoes, we 
decided to search for IN mutants specifically 
defective for TRN-SR2 binding. We previously 
characterized the TRN-SR2 interaction interface 
to identify key amino acids in the viral IN and 
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determined the hot spots for the interaction, 
namely the amino acids R262/R263/K264 and 
K266/R269 in IN (27). Independent 
confirmation of the role of R262, R263 and 
K264 was provided by Larue et al. (38).  
We next decided to introduce specific IN 
interface mutants in NL4-3 backbones to study 
their effect on viral replication. However, since 
IN is an essential component of the 
nucleoprotein complex in the budding virus and 
of the reverse transcription complex (RTC), IN 
mutations can result in pleiotropic effects 
extending well beyond the integration step. It is 
well established that some IN mutants negatively 
affect reverse transcription (44,45). Out of the 
five amino acids identified as hot spots for 
interaction with TRN-SR2 (Figure 1), the 
K266A and R269A single point mutants as well 
as the double mutants R262A/R263A and 
R262A/K264A were reported before to 
negatively affect reverse transcription (44), 
confounding the detection of replication defects 
beyond reverse transcription, such as blocked 
nuclear import.  
Here we describe a virus carrying an IN mutant 
with reduced affinity for TRN-SR2 (NL4-3
INR263A/K264A) that still displays wild-type reverse 
transcriptase activity. Demonstration of a 
nuclear import defect for this virus implies that 
the interaction between IN and TRN-SR2 
mediates HIV PIC nuclear import.
Experimental procedures 
Plasmids and Recombinant protein purification - 
Recombinant proteins were expressed in E. coli
strain BL21-CodonPlus (DE3). Recombinant 
His6-tagged HIV-1 IN (46) and recombinant 
GST-tagged TRN-SR2 (18) were purified as 
described previously.  His6-tagged HIV-1 IN 
was expressed using pINSD.His (obtained 
through the AIDS Research and Reference 
Reagent Program). The mutations in pINSD.His 
were introduced by site-directed mutagenesis
using the Kirsch and Joly method (47). 
Megaprimers were ordered and used to perform 
a full round PCR on the pINSD.His plasmid. For 
the INR263A/K264A mutation following 
megaprimers were used: pINSD-RK263toA-s:  
5’CAATCATCACCTGCCATCTGTTTTCCATAATCCCT
GATGATCTTTGCTGCTGCTCTTGGCACTACTTTTAT
GTCACTATTATCTTG 3’ and pINSD-RK263toA-as: 
5’ CAAGATAATAGTGACATAAAAGTAGTGCCAA 
GAGCAGCAGCAAAGATCATCAGGGATTATGGAAA
ACAGATGGCAGGTGATGATTG 3’. All plasmid 
constructs used in this work were verified via 
sequence analysis. 
AlphaScreen protein-protein interaction assay - 
The AlphaScreen binding assay was performed 
as described previously (27). In brief, proteins 
were all diluted to 5× working solutions in the 
assay buffer (25 mM Tris [pH 7.4], 150 mM 
NaCl, 1 mM MgCl2, 2 mM DTT, 0.1% [v/v] 
Tween-20, and 0.1% [w/v] bovine serum 
albumin [BSA]). First, 10 μL of the GST-TRN-
SR2 was pipetted into the wells, followed by 5 
μL of a His6-IN dilution series. The plate was 
sealed and left to incubate for 1 h at 4°C. Next, 
10 μL of a mix of Ni2+ chelate acceptor and 
glutathione donor AlphaScreen beads 
(PerkinElmer) was added. Plates were then 
incubated for 1 h at 30°C and analyzed using an 
EnVision Multilabel Reader (PerkinElmer) 
according to the manufacturer’s instructions. 
Points for which quenching of the signal 
occurred through excess of either binding 
partner (“hooking” as referred to by the 
supplier), were excluded from the final plot. 
Integrase activity assays - 3’-processing activity 
was measured by detection of radioactively 
labeled products by denaturing gel 
electrophoresis and was performed as described 
previously (48). Briefly, 500 nM IN was 
incubated for 7.5 min at 37°C with 20 nM of the 
radioactively labeled oligonucleotide substrate 
(INT1, 32P-5’ GTGTGGAAAATCTCTAG
CAGT 3’; INT2, 5’ACTGCTAGAGATTT
TCCACAC 3’). The final reaction mixture 
contained 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) pH 7.5, 
5 mM dithiothreitol (DTT), 10 mM MgCl2, 0.5% 
(v/v) polyethylene glycol 8000, 0.5% BSA and 
15% dimethylsulfoxide (DMSO). The reactions 
were stopped by the addition of 50% vol 
formamide. Samples were loaded on a 15% 
denaturing polyacrylamide/urea gel. The extent 
of 3’-processing was measured based on the 
respective intensity of -2 bands relative to the 
total radioactivity present in the lane. These data 
were determined using the OptiQuant 
Acquisition and Analysis software (Perkin 
Elmer Corporate). Strand-transfer activity was 
measured with a quantitative ELISA as 
described previously (49). 
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Cell culture - HeLaP4 cells (obtained from the 
NIH Reagent Program) were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 50 μg/ml gentamicin (Gibco, 
BRL) and 5% fetal calf serum (International 
Medical, Belgium). Cells were incubated at 
37°C and 5% CO2 in a humidified atmosphere. 
Two different HeLaP4 cell lines stably knocked 
down for importin-α3  were generated by 
transduction with two different lentiviral vectors 
expressing shRNAs targeting the importin-α3  
mRNA, called sh93 and sh97 (Sigma, clone-id 
NM_002268.3-1814s1c1 and NM_002268.3-
605s1c1). A control cell line was established 
using a control vector expressing a scrambled 
shRNA referred to as shSCR (Sigma, product 
number SHC002). These lentiviral transfer 
plasmids were a kind gift from Dr. R. Hoeben 
(Leiden University Medical Center, The 
Netherlands). The shRNA expressing transfer 
plasmids are based on the pLKO.1 plasmid 
(Sigma) containing a puromycin resistance 
cassette. After transduction cells were selected 
and grown in DMEM as described above with 
the addition of 1 μg/ml puromycin. MT-4 cells 
(obtained from the AIDS Research and 
Reference Reagent Program, Division of AIDS, 
NIAID, NIH, from Dr. Douglas Richman ) were 
grown in RPMI 1640 (GIBCO 461 BRL) 
supplemented with 12% FCS and 50 μg/ml 
gentamicin. Human peripheral PBMCs were 
purified from fresh buffy coats of anonymous 
voluntary donors using Lymphoprep (Axis-
Shield PoC AS, Oslo, Norway) following the 
manufacturer’s protocol. Subsequently, PBMCs 
were maintained and stimulated in RPMI 1640
supplemented with 15% FCS, 20 U/ml IL-2 and 
10.
Western blotting - For western blotting, protein 
concentrations of 1% SDS whole cell extracts 
were determined using the BCA protein assay 
(Thermo Scientific Pierce) and after separation 
by SDS-PAGE 25 μg of each extract was 
electroblotted onto polyvinylidene difluoride 
membranes. Membranes were probed with 
monoclonal antibodies against importin-α3 
(1:500 dilution) (ab6039, abcam) and β-actin 
(1:5000 dilution) (A5441 Sigma) antibodies 
were used to confirm equal loading. Detection 
was performed using horseradish peroxidase-
conjugated antibodies (Dako) and 
chemiluminescence (Pierce ECL+, Thermo 
scientific).
Viruses and viral vectors - The viral molecular 
clones pNL4-3 and pNL4-3.Luc.RE- were 
obtained through the AIDS Research and 
Reference Reagent Program. Mutations in 
pNL4-3 and pNL4-3.Luc.RE- were introduced 
by site-directed mutagenesis using the Kirsch 
and Joly method (47). Briefly, a sequence 
comprising the integrase coding region, 
amplified by PCR using pNL4-3 as a template, 
was cloned into pCR4-Topo (Invitrogen). This 
plasmid was then used to perform Kirsch and 
Joly site-directed mutagenesis using the pINSD-
RK263toA-s and pINSD-RK263toA-as primers. 
The mutated IN sequence was then cloned back 
into pNL4-3 or pNL4-3.Luc.RE- using two 
unique restriction sites (AgeI and PflMI).Viruses 
were produced by polyethylenimine (PEI)-
mediated transfection of 293T cells using 20 μg 
of the viral molecular clone pNL4-3 per 10 cm 
dish, for vectors an extra 5 μg of the pMD.G 
plasmid encoding the vesicular stomatitis virus 
glycoprotein (VSV-G) (50) was added. Two and 
three days post transfection, the supernatant was 
harvested, filtered through 0.22 μm pore-size 
syringe filters (Sartorius), concentrated by 
centrifugal filtration using Vivaspin 
concentrators (Millipore) and treated with 
DNase I (Roche) for 1 h at 37°C. For the single 
round experiments HeLaP4 cells (104 cells) 
stably depleted of importin-α3 and control cells 
were seeded into 96-well plates. One day later 
cells were infected in triplicate with 2 dilutions 
(21000 and 7000 pg  p24 ) of VSV-G
pseudotyped single-round HIV-1 virus in a total 
volume of 100 μl per well. Each well was lysed 
72 h after infection using 50 μl of lysis buffer 
(50 mM Tris/HCl, pH 7.3, 200 mM NaCl, 0.2% 
NP40, 5% glycerol) and was analyzed for firefly 
luciferaseactivity (ONE-Glo™, Promega, 
Belgium) according to the manufacturer’s 
protocols. Chemiluminescence was measured 
with a Glomax luminometer (Promega, 
Belgium). The protein concentration of each 
sample was determined (BCA Protein Assay Kit, 
Thermo Scientific Pierce) and readouts were 
normalized to 1 μg total protein. For the 
breakthrough experiments HeLaP4 cells (3.104
cells), MT-4 cells (105 cells) or PBMCs (106
cells) were infected with virus amounting to 
30,000, 50 or 20,000 pg of p24, respectively. 
Starting three days after infection, supernatants 
were sampled daily.
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Q-PCR quantification of HIV DNA species - 106
MT-4 cells were infected with 106 pg p24 of 
virus. Inhibitors, if present, were 2 μM 
zidovudine (AZT) or 0.6 μM raltegravir (Ral). 
At 2 h post-infection, supernatants were replaced 
with fresh Dulbecco's Modified Eagle Medium 
(DMEM) medium containing DMSO, AZT or 
Ral. Ritonavir (4 μM) was added to all samples 
to restrict replication to a single round. At 
distinct time points after infection, cells were 
lysed by the addition of a 10 mM Tris (pH 8.0) 
buffer containing 0.02% triton-X-100, 0.02% 
sodium dodecyl sulphate (SDS), 1 mM 
ethylenediaminetetraacetic acid (EDTA), and 0.8 
mg of proteinase K/ml and incubated for 1 h at 
56°C. Q-PCR was performed directly on the 
lysates. A specifically designed set of TaqMan 
probe and primers was used to quantify the 
amount of each specific HIV-1 DNA form in the 
cell lysate as described previously (34,51,52).
For the quantification of reverse transcripts (total 
HIV-1 DNA), the forward primer 5′-
ATCAAGCAGCCATGCAAATGTT-3′, the 
reverse primer 5′-CTGAAGGGTACTAGT 
AGTTCCTGCTATGTC-3′, and the probe 5′-
(FAM)-ACCATCAATGAGGAAGCTGCAGA 
ATGGGA-(TAMRA)-3′ were used. For the 
quantification of 2-LTR circles, the forward 
primer 5′-GTGCCCGTCTGTTGTGTGACT-3′, 
the reverse primer 5′-CTTGTCTTCTT 
TGGGAGAGAATTAGC-3′, and the probe 5′-
(FAM)-TCCACACTGACTAAAAGGGTCTGA 
GGGATCTCT-(TAMRA)-3′ were used. 
Quantification of integrated proviruses was 
performed by nested Alu-PCR, as described 
previously (51). For the first-round, the forward 
primer, 5’-CTAACTAGGGAACCCACTGCT 
TA-3’ and the reverse primer, 5’-
TGCTGGGATTACAGGCGTGAG-3’ were 
used. The reaction contained 2 mM MgCl2, 250 
μM dNTPs, 400 nM primers, 1.25 U Taq DNA 
polymerase (Fermentas), 75 mM Tris-HCl (pH 
8.8), 20 mM (NH4)2SO4 and 0.01% Tween 20. 
For the Q-PCR, the forward primer, 5’-
AGCTTGCCTTGAGTGCTTCAA-3’, the 
reverse primer, 5’-TGACTAAAAGGGTCTG
AGGGATCT-3’ and the probe 5’-(FAM)-
TTACCAGAGTCACACAACAGACGGGCA-
(TAMRA)-3’ were used. In each sample RNase 
P DNA was quantified as the endogenous 
control (Applied Biosystems). For each real-time 
PCR analysis, a standard curve was generated 
using dilutions of a representative sample. No-
template controls (no DNA added to the PCR 
mixture) were run with each experiment. 
Reactions contained 1× iQ supermix (Biorad), 
300 nM forward and reverse primer and 200 nM 
probe. After initial incubations at 95°C for 5 
min, 50 cycles of amplification were carried out 
at 95°C for 10 s, followed by 30 s at 55°C. 
Reactions were analyzed using the 
LightCycler®480 (Roche).
PIC Nuclear Import Assay – The PIC nuclear 
import assay was performed with adaptations to 
the previously described protocol (37). 293T 
cells were transfected with 15 μg pVpr-IN-eGFP 
(Vpr and IN were cloned into the pEGFP-N1 
vector from Clontech Laboratories), 15 μg 
pNL4-3.Luc.R-.E- (obtained from the AIDS 
Reference and Reagent Program), and 5 μg of 
the pMD.G plasmid encoding the vesicular 
stomatitis virus glycoprotein (VSV-G) (50).
Supernatant was collected after 48 h, filtered 
through a 0.45 μm pore-size filter (Sartorius), 
and then concentrated by ultracentrifugation at 
27500 rpm for 1 h 45 min. p24 was measured 
with the INNOTEST HIV Antigen mAb kit of 
Innogenetics. A viral inoculum of 3.106 pg p24 
was used to infect 30,000 HeLa-P4 cells. Five 
hours after infection, cells were fixed with 2% 
paraformaldehyde. The nuclear lamina was 
visualized by staining with a monoclonal anti-
lamin A/C antibody (Santa Cruz, sc-7292) and a 
secondary goat anti-mouse IgG Alexa-Fluor 633. 
Three-dimensional stacks of fixed cells were 
acquired with a Zeiss LSM510 multiphoton 
confocal microscope (Cell Imaging Core CIC, 
University of Leuven) equipped with a Plan-
Apochromat 63x/1.4 Oil DIC objective. The Z-
step size was 0.3 μm. Ar and HeNe laser lines 
were used for EGFP and Alexa-633 excitation. 
A sequential image acquisition was used. The 
quantification of the PICs was performed using a 
homemade MatLab routine (The MathWorks, 
Inc.). In brief, after adequate image processing, 
points were automatically detected using an 
intensity threshold. A fluorescent spot was 
assigned as a PIC if at least two connecting 
pixels are above the threshold and if the 
fluorescent signal is present in at least two 
consecutive frames (z planes). PICs were 
classified as cytoplasmic, in the nucleus or at the 
nuclear membrane based on the nuclear lamin 
staining. 
Results 
Selection of mutants defective for IN/TRN-SR2 
interaction to study nuclear import of HIV  
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We previously characterized the TRN-SR2 
interaction interface to identify key amino acids 
in viral IN.  Next we introduced these specific 
IN interface mutants in NL4-3 backbones to 
study their effect on viral replication. Out of the 
five amino acids identified as hot spots for 
interaction with TRN-SR2 (Figure 1), the 
K266A and R269A single point mutants as well 
as the double mutants R262A/R263A and 
R262A/K264A were reported before to 
negatively affect reverse transcription (44), 
confounding the detection of replication defects 
beyond reverse transcription, such as a possible 
block in nuclear import. Therefore we tested the 
remaining mutants, namely the single point 
mutants R262A, R263A, K264A and the double 
point mutant R263A/K264A for their binding to 
TRN-SR2 using AlphaScreen (Figure 1B). 
AlphaScreen is a bead-based protein-protein 
interaction assay in which binding of the 
proteins results in light emission (AlphaScreen 
signal). The single point mutants R262A, R263A 
and K264A did not affect TRN-SR2-binding 
(data not shown) whereas INR263A/K264A showed a 
reduction in AlphaScreen signal. We therefore 
performed an outcompetition AlphaScreen  
experiment to quantify the change in affinity to 
TRN-SR2 compared to wild type (WT) IN. We
outcompeted the binding between GST-TRN-
SR2 and His-tagged WT IN or INR263A/K264A with 
untagged CTD of IN and calculated the IC50 of 
IN CTD in three independent experiments each 
performed in duplicate. The IC50 for 
outcompetition with IN CTD, was 172 nM 
(CI95% = 24.6 to 237.9 nM) for WT IN and 74 
nM (CI95% = 45.95 to 119.5 nM)  for 
INR263A/K264A, pointing to a significant 2.3-fold 
lower affinity of mutant IN for TRN-SR2 than 
WT IN p = 0.0154  (Figure 1B).   
Next we compared the catalytic activities of WT 
IN, the double mutant INR263A/K264A and the 
enzymatically dead IND64A (53). The 3’-
processing activity was severely affected, as 
INR263A/K264A only showed residual activity in 
comparison with WT IN (Figure 1C). Both 
INR263A/K264A and IND64A were defective for strand 
transfer as determined in a quantitative ELISA 
assay (Figure 1D). The lack of catalytic activity 
of the INR263A/K264A mutant however did not 
hamper the analysis of reverse transcription or 
nuclear import as these steps precede 
integration. In a previous study we showed using 
size exclusion chromatography that the 
R262A/R263A/K264A substitutions in IN do 
not affect IN oligomerization (27). We hence 
decided to study INR263A/K264A in the context of 
the virus.  
Characterization of HIV-1 NL4-3 virus carrying 
INR263A/K264A
The INR263A/K264A mutations were inserted into a 
molecular clone of HIV (pNL4-3). Mutant and 
WT virus were harvested after transient 
transfection of 293T cells and normalized for 
p24 level or reverse transcriptase activity. 
HeLaP4, MT-4, and peripheral blood 
mononuclear cells (PBMC’s) isolated from 
donor blood samples were infected with equal 
amounts of WT or INR263A/K264A virus. Viral 
replication was monitored by sampling the 
supernatant as long as cells were viable. As 
expected from the reduced IN activities, 
INR263A/K264A virus was completely replication-
deficient in primary cells (Figure 1E) as well as 
in HeLaP4 and MT-4 cells (data not shown).  
In 2010, a potential role of importin-α3 in HIV 
nuclear import was reported (11). Later the IN 
amino acids R263 and K264 were claimed to be 
involved in the binding to importin-α3(54). We 
therefore analyzed the effect of importin-α3 
knockdown on HIV replication. We generated 
two stable importin-α3 knockdown cell lines 
(sh93 and sh97) and infected those with HIV 
NL4.3-Fluc. Potent knockdown of importin-α3 
(95% and 99%, respectively) did not 
significantly reduce HIV infection compared to 
control cells (shSCR) (Figure 2). In comparison 
a 70% knockdown of TRN-SR2 resulted in a 10-
fold reduction of HIV infection (18). Due to the 
uncertain role for importin-α3 in HIV-1
infection, the INR263A/K264A mutant was used to 
study the specific role of the IN/TRN-SR2 
interaction during HIV nuclear import. 
To pinpoint at which step viral replication of the 
INR263A/K264A virus was blocked, we monitored 
formation of viral DNA intermediates during 
single-round HIV-1 infection by Q-PCR for late 
reverse transcripts, integrated copies and 2-LTR 
circles. To control for the 3’-processing 
deficiency of INR263A/K264A, we not only 
compared the mutant to WT virus but also to the 
NL4-3 IND64N/D116N/E152Q mutant virus (55). We 
generated this triple mutant, which has a mutated 
catalytic triad and lacks all enzymatic activity, as
a more stringent control than the D64A mutant 
used previously (53).
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Late reverse transcripts were measured by Q-
PCR at 4, 8, 10 and 24 hours post-infection 
(Figure 3A and B). The HIV NL4-3 INR263A/K264A
mutant produced a similar number of reverse 
transcripts (taken at 8 and 10 hours post-
infection) as WT virus whereas the 
IND64N/D116N/E152Q mutant produced less reverse 
transcripts (93.6 ± 8.8% for NL4-3 INR263A/K264A
p = 0.369 and 68.9 ± 4.5% for NL4-3
IND64N/D116N/E152Q p = 0.01). Conversely, the 
chain terminator AZT effectively blocked 
reverse transcription of all viruses whereas the 
strand transfer inhibitor raltegravir (Ral) did not 
affect reverse transcription (Figure 3A and B). 
Next, integrated viral DNA was measured by Q-
PCR at 48 hours post-infection. The number of 
integrated copies of WT NL4-3 was effectively 
reduced by addition of AZT or Ral. Even though 
reverse transcription activities were comparable 
to WT virus (gray bars), both NL4-3
INR263A/K264A mutant virus as well as 
IND64N/D116N/E152Q displayed a block in integration 
compatible with their loss of 3’-processing and 
strand transfer activities (Figure 3C and D).
Taken together these experiments indicate that 
these mutants both affect a step after RT, either 
during nuclear import or integration. 
Next, we measured the formation of 2-LTR 
circles as an indirect measure for nuclear import 
at 24 hours post-infection (35). As expected (56) 
a 10–fold increase in the number of 2-LTR 
circles was evidenced when Ral was added 
during infection with WT NL4-3 (gray bars) 
(Figure 3E and F). Due to the block in 
integration the virus NL4-3 IND64N/D116N/E152Q also 
produced increased numbers of 2-LTR circles, 
reaching comparable levels as WT NL4-3 
supplemented with Ral. No further increase 
upon addition of Ral was observed as expected 
for a catalytically dead mutant (Figure 3F). The 
Q-PCR data on the 2-LTR circles of the 
INR263A/K264A mutant require careful analysis 
since a block of integration will typically result 
in increased levels of 2-LTR circles but a
concomitant block in nuclear import will lead to 
reduced 2-LTR circle formation (18,20,21,36).
Although the number of 2-LTR circles of the 
INR263A/K264A mutant was 2-fold higher than that
of WT virus (Figure 3E), this increase was much 
lower than expected for a virus affected at the 
integration step (on average 10-fold higher) 
(Figure 3F). Even though the different viral 
preps were normalized for p24 and showed a 
comparable extent of reverse transcription, 2-
LTR circles of the INR263A/K264A mutant increased 
to levels that were 2.5-fold lower (p = 0.0004) 
than those of the catalytic dead mutant. Upon 
addition of Ral to WT virus a 10-fold increase in 
2-LTR circles was measured (p = 0.0002), which 
is typically seen with a block in integration. 
These data indicate that NL4-3 INR263A/K264A is 
also affected at a step following reverse 
transcription and before integration, thus most 
presumably at the nuclear import step. 
Nuclear import defect of NL4-3 INR263A/K264A 
virus  
To confirm the effect of INR263A/K264A on HIV 
nuclear import we finally performed a PIC 
nuclear import assay (37) (see materials and 
methods for more details). We produced two 
distinct IN-eGFP labeled viruses, one with WT 
IN and the other with the INR263A/K264A double 
mutant. Five hours after infection the 
fluorescently labeled PICs were visualized using 
confocal microscopy (Figure 4A). The ratio of 
nuclear PICs over cytoplasmic PICs (percentage 
nuclear PICs) is a measure of nuclear import 
(18). To analyze HIV carrying INR263A/K264A, two 
independent experiments, with distinct 
productions of both the WT and the INR263A/K264A 
mutant virus, were performed. Cytoplasmic and 
nuclear PICs were counted (Figure 4B). The 
ratio of nuclear versus cytoplasmic PICs, was 
calculated for both independent experiments.  
The difference between the distributions of the 
% nuclear PICs for WT and INR263A/K264A mutant 
PICs was highly significant (WT, n = 51 cells;
INR263A/K264A, n = 49 cells; p = 0.0054, Mann-
Whitney test) and (WT, n = 41 cells; 
INR263A/K264A, n = 44 cells; p = 0.0095, Mann-
Whitney test) (Figure 4B). Combining the data 
sets of the two individual experiments the p-
value further decreased to 0.0001 (WT, n = 92 
cells; INR263A/K264A, n = 93 cells). The mean %
nuclear PICs calculated with 95% confidence 
interval was 4.1% for the WT (95% confidence 
interval, CI [3.5%; 4.7%]) and 2.4% for 
INR263A/K264A (95% CI [2.1%; 2.8%]). When the 
percentage of cells that maximally contain a 
specific number of nuclear PICs was plotted, 50
% of the INR263A/K264A mutant virus infected cells 
contained 0 to 1 % nuclear PICs, whereas 50 % 
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of the WT virus infected cells contained 0 to 3 % 
nuclear PICs, in line with a reduced nuclear 
import for HIV INR263A/K264A and corroborating 
the Q-PCR results. 
In a following experiment we evaluated the 
combined effect of TRN-SR2 depletion and 
interface mutants on PIC nuclear import.  Stable 
TRN-SR2 depletion (shTR3) resulted in a
significant reduction in nuclear PICs compared 
to control cells (shSCR) (WT in shSCR cells,
n = 55 cells; WT in shTR3 cells, n = 49 cells; p
= 0.0023, Mann-Whitney test)  (Figure 4C) as
shown previously after transient depletion of 
TRN-SR2 (18). The mean % nuclear PICs 
calculated with 95% confidence intervals was 
2.2% for the control cells (95% confidence 
interval, CI [0.8%; 3.6%]) and 0.5% for TRN-
SR2 knockdown cells (95% CI [0.3%; 0.7%]). 
We plotted the percentage of cells that 
maximally contain a specific percentage of 
nuclear PICs.  For example, 95 % of the TRN-
SR2 knockdown cells contain 0 to 2 % nuclear 
PICs, whereas 95 % of the control cells contain
0 to 5 % nuclear PICs. In parallel the 
INR263A/K264A virus was tested both in shSCR 
cells, n = 50 cells and in shTR3 cells,
n = 50 cells. Also in this experiment nuclear 
import of the WT virus was significantly higher 
than that of the INR263A/K264A mutant virus; 
p = 0.0167. In shTR3 cells data for the WT virus 
(mean % nuclear PICs = 0.5) were not 
statistically different from data for the 
INR263A/K264A mutant virus in shSCR cells (mean 
% nuclear PICs = 0.7); p = 0.5836. For the 
INR263A/K264A mutant virus in shTR3 cells the 
mean % nuclear PICs was calculated with 95% 
confidence intervals as 0.2% (95% confidence 
interval, CI [0.1%; 0.3%]) which was 
significantly different from the INR263A/K264A 
mutant virus in shSCR cells; p = 0.002 
indicating an additive effect of TRN-SR2 
depletion and interface mutations. 
Discussion 
In 2008 we identified TRN-SR2 as an 
interaction partner of HIV-1 integrase by yeast-
two-hybrid-screening (18). Using RNAi 
technology, we could demonstrate the crucial 
role of TRN-SR2 during HIV replication both in 
dividing and non-dividing cells (18). 
Independently, two genome-wide siRNA screens 
also identified TRN-SR2 as a crucial cofactor 
for HIV replication (16,17). While this paper 
was in revision two papers were published 
revealing the crystal structure of TRN-SR2 
(57,58). The TRN-SR2 mutant, D750A/D751A, 
was defective for interaction with CPSF6 and 
proved unable to support HIV-1 infection, 
although reportedly retaining WT level of HIV 
IN and ASF/SF2 binding (57). In our hands 
TRN-SR2D750A/D751A displayed a slightly reduced 
affinity for IN but was strongly impaired for 
binding to unphosphorylated ASF/SF2, 
suggesting that this mutant is generally reduced 
in its cargo binding capacity (data not shown). 
Although indirect evidence suggests that the 
IN/TRN-SR2 interaction mediates HIV nuclear 
import, we thus needed to specifically block this 
interaction to corroborate its role in HIV nuclear 
import. To uncouple the effect of TRN-SR2 
knockdown from the possible cytoplasmic 
accumulation of CPSF6 or other cargoes, we 
decided to search for IN mutants selectively 
defective for TRN-SR2 binding. We previously 
characterized the TRN-SR2 interaction interface 
to identify key amino acids in IN and determined 
as hot spots the amino acids R262/R263/K264 
and K266/R269 (27). Independent confirmation 
of the role of R262, R263 and K264 was 
provided by Larue et al. (38).  
Here we aimed to insert specific IN interface 
mutants in HIV molecular clones to study their 
effect on viral replication. However, out of the 
five amino acids identified as hot spots for 
interaction with TRN-SR2, the K266A and 
R269A single point mutants as well as the 
double mutants R262A/R263A and 
R262A/K264A were reported to negatively 
affect reverse transcription (44), confounding the 
detection of replication defects beyond reverse 
transcription, such as blocked nuclear import. 
Recently Li et al. reported on the INK264E mutant 
that is defective for 3’ processing and strand-
transfer in typical in vitro assays, but still 
displayed concerted integration activity. 
Unfortunately, reverse transcription by HIV-1 
INK264E was reduced by 3- to 16-fold, obscuring 
further analysis (59). Therefore we tested the 
remaining alanine mutants, namely the single 
point mutants R262A, R263A, K264A and the 
double point mutant R263A/ K264A for their 
binding to TRN-SR2. The single point mutants 
R262A, R263A, K264A did not affect TRN-
SR2-binding whereas the double point mutant 
R263A/ K264A inhibited TRN-SR2 binding 2.3-
fold (Figure 1B). We therefore selected the 
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INR263A/K264A mutant that interacts less with 
TRN-SR2 and does not perturb reverse 
transcription, allowing us to study the role of the 
TRN-SR2/IN interaction in the nuclear import of 
the PIC. In the past several attempts have been 
made to define potential NLSs in IN. Two 
stretches of amino acids, 211KELQKQITK219 and 
261PRRKAK266 , were described as a potential 
bipartite NLS (8). Our analysis of the IN/TRN-
SR2 interface has allowed us to confirm the 
following sets of amino acids in IN: 
R262/R263/K264 and K266/R269 (27). Lysine 
264 was found to be acetylated by p300 by 
Cereseto et al. (60). Importin 7 and importin-α3
have both been implicated as nuclear import 
factors for HIV through a direct interaction with 
IN (14,54). Although importin 7 was later 
invalidated as HIV-1 nuclear import factor (11),
R263 and K264 were reported as interacting 
amino acids. Previously the same two IN amino 
acids were implicated in the interaction between 
IN and importin-α3 (54). In our hands potent 
knockdown of importin-α3 did not affect HIV 
replication bringing into question the prior 
claims for a significant role for importin-α3 in
HIV-1 replication (Figure 2).  To assess the 
impact of a deficient IN/TRN-SR2 interaction on 
the nuclear import of HIV, the INR263A/K264A 
interface mutations were inserted into a
molecular clone of HIV (pNL4-3) resulting in a 
replication-deficient virus. As in vitro analysis 
of the mutant integrase has evidenced a strong 
defect in catalytic activity, it was expected that 
the mutant virus does not integrate and is 
replication defective. To pinpoint at which step 
replication is inhibited, we performed Q-PCR 
analyses on the different viral DNA 
intermediates. In parallel we investigated the 
IND64N/D116N/E152Q catalytic triad mutant virus to 
control for the effect of defective 3’-processing 
on the formation of the viral DNA species. It is 
well known that a block in integration leads to 
an accumulation of 2-LTR circles in the nucleus 
(34). Indeed, both addition of Ral during 
infection with WT NL4-3 and infection with 
NL4-3 IND64N/D116N/E152Q virus resulted on 
average in a 13-fold increase in 2-LTR circles.
Remarkably, infection with NL4-3 INR263A/K264A,
which is also defective for integration, only 
resulted on average in a 6-fold increase in 2-
LTR circles. Compared to WT NL4-3, NL4-3
INR263A/K264A displayed an increased number in 2-
LTR circles, due to its defective integration.
However in comparison with the number of 2-
LTR circles for WT NL4-3 supplemented with 
Ral and NL4-3 IND64N/D116N/E152Q on average a 
relative 2-fold decrease was measured (p = 
0.01), suggesting a defect in nuclear import. This 
reduction may still be an underestimate of the 
true effect, since lack of IN strand transfer 
activity (as observed for INR263A/K264A in vitro) is 
associated with an increase in 2-LTR circle 
formation due to aborted integration that may 
counteract the reduction in circles resulting from 
reduced PIC import. 
Although well-established, Q-PCR analysis of 2-
LTR circles is an indirect way to measure 
nuclear import of HIV. Therefore we 
additionally performed a cellular PIC nuclear 
import assay, which allows us to directly follow 
HIV PICs in infected cells (18,37). In this assay 
IN-eGFP is trans-incorporated into viral 
particles through Vpr fusion, enabling 
visualization by confocal microscopy. The ratio 
of nuclear to cytoplasmic PICs allows for direct 
quantification of nuclear import. Whereas 2-
LTR accumulation is typically measured at 24 h
after infection prior to dilution by cell division, 
nuclear PICs are imaged by fluorescence at 5 h
post infection since integration is believed to 
dissassemble the PICs. Albanese et al. 
performed a kinetics experiment to quantify the 
number of nuclear PICs at different time points 
from 3 to 24 hours after infection and showed
that the maximum number of intranuclear PICs 
was indeed reached after 6 hours (37).  
This PIC import assay further corroborated the 
block in nuclear import observed with the 
INR263A/K264A virus in comparison with WT virus. 
The reduction in nuclear PICs of the 
INR263A/K264A virus was similar to the reduction 
seen after TRN-SR2 depletion. When analyzing 
INR263A/K264A in shTR3 cells the combination of 
both partial TRN-SR2 depletion and 2-fold 
reduced IN-TRN-SR2 interaction resulted in an 
additive effect on the inhibition of nuclear 
import. 
The on average 2-fold reduction in nuclear PICs 
and the 2-fold drop in 2-LTR formation and was 
perfectly in line with the 2.3-fold lower binding 
affinity of INR263A/K264A for TRN-SR2 compared 
to WT IN. 
We describe here how the NL4-3 virus, carrying 
INR263A/K264A which is deficient for interaction 
with TRN-SR2, is blocked at the nuclear import 
step. These results directly associate HIV 
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integrase and TRN-SR2 for a common role 
during HIV nuclear import. Representing a 
significant bottleneck for HIV replication, 
nuclear import is of utmost importance for 
successful infection of host cells. The evidence 
provided supports a mechanism whereby the 
TRN-SR2/IN interaction directly mediates 
nuclear import of the viral PIC, validating this 
protein-protein interaction as a promising target 
for antiviral therapy.  
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Figure 1: INR263A/K264A has a reduced binding affinity for TRN-SR2 and HIV carrying 
INR263A/K264A is replication-defective. (A) Structure of the C-terminal domain of HIV-1 IN based on 
PDB ID: 1EX4 (61). Amino acids R262, R263 and K264, that are important for the TRN-SR2/IN 
interaction and reportedly do not affect reverse transcription as single mutants (44) are colored in 
green.  Amino acids K266 and R269, that are important for the TRN-SR2/IN interaction but were 
reported to negatively affect reverse transcription, are colored in blue. (B) AlphaScreen-based 
analysis of the outcompetition of the interaction between his6-tagged WT IN or INR263A/K264A and 
GST-TRN-SR2 using untagged IN CTD. IN CTD was titrated out over a fixed concentration of IN 
(80 nM) and GST-TRN-SR2 (20 nM) and light emission was measured. The graph displays an 
average of three experiments each performed in duplicate. (C) A representative autoradiogram of an
IN 3’-processing assay. The positions of unreacted DNA substrate and 3′-processed products are 
indicated. In the Graph, the mean DLU/mm²± SD from triplicate samples from two separate 
experiments is shown, with the WT IN 3’-processing activity set to 100 %. INR263A/K264A shows 5.1% ±
1.7% 3’-processing activity compared to WT whereas the catalytically dead IND64A mutant shows no 
activity (0.3% ± 0.3% ). (D) The percentage normalized optical density (OD) of an ELISA measuring 
strand transfer activity is displayed. The mean OD ± SD from quadruplet samples from three 
experiments is shown, with the WT IN OD set to 100 %. Both INR263A/K264A and IND64A show less than 
1.7%± 1.2%  strand transfer activity compared to WT. (E) Human PBMCs and were infected with 
20,000 pg p24 of HIV NL4-3 WT and HIV NL4-3 INR263A/K264A. Starting three days after infection, 
supernatants were sampled daily. The mean p24 value ± SD from triplicate samples from one of two 
representative experiments is shown. 
Figure 2: Potent knockdown of importin-α3 does not inhibit HIV infection. (A) A representative 
western blot shows the levels of importin-α3 (IPOA3) in control cells (shSCR) and importin-α3 
knockdown cells (sh93 and sh97) . Anti beta-actin antibody is used as a loading control. (B) HeLaP4 
cells depleted of importin-α3 (sh93 and sh97)  and control cells (shSCR) were challenged with two 
dilutions of VSV-G pseudotyped HIV-1 NL4-3 luciferase reporter virus. Three days post infection 
Fluc activity was measured and normalized to the total amount of protein in the cell lysates. Graphs 
show the mean values of Fluc light units per μg protein (RLU) ± SD of one representative experiment 
out of two performed in triplicate.
Figure 3: Replication of HIV NL4-3 INR263A/K264A is blocked at the stage of nuclear import. For Q-
PCR, MT-4 cells were infected with 106 pg p24 of HIV NL4-3 WT, IND64N/D116N/E152Q or INR263A/K264A 
virus. At distinct time points after infection, cells were harvested and viral DNA species were 
quantified by Q-PCR (n = 3, data are represented as mean ± SD). (A and B) Kinetics of late reverse 
transcripts normalized for RNaseP. (C and D) The number of integrated copies at 48 hours post-
infection normalized for RNaseP. (E and F) The number of 2-LTR circles at 24 hours post-infection 
normalized for RNaseP.  
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Figure 4: Reduction in nuclear import of HIV NL4-3 INR263A/K264A. Five hours after infection with 
eGFP-labeled IN virus, HeLaP4 cells were fixed and analyzed by laser-scanning confocal 
microscopy. The ratio of nuclear/cytoplasmic green PICs was quantified (percentage nuclear PICs). 
(A) Representative slice of a stack of WT and INR263A/K264A mutant PIC virus infected cells. The 
nuclear lamina was immunostained with anti-lamin A/C (red). PICs are identified as green dots and 
nuclear PICs are highlighted by white arrows. Images are derived from confocal Z-stacks. (B) 
Cumulative distribution of the percentage of cells containing a certain ratio of nuclear over 
cytoplasmic PICs. Two independent experiments, with distinct productions of both the WT and the 
INR263A/K264A mutant virus, were performed (WT, n = 51 cells; INR263A/K264A, n = 49 cells; p = 0.0054, 
Mann-Whitney test) (WT, n = 41 cells; INR263A/K264A, n = 44 cells; p = 0.0095, Mann-Whitney test).  
(C) Nuclear import was measured in control cells (shSCR) or cells stably depleted for 75 %  for TRN-
SR2 (shTR3). The cumulative distribution of the percentage of cells containing a certain ratio of 
nuclear over cytoplasmic PICs is shown forWT virus in shSCR, n = 55 cells, WT in shTR3, n = 49 
cells; INR263A/K264A in shSCR, n = 50 cells and INR263A/K264A in shTR3, n = 50 cells. Nuclear import of 
the INR263A/K264A mutant virus was significantly lower than for WT virus; p = 0.0167, Mann-Whitney 
test, whereas import of the WT virus in shTR3 cells was not statistically different from that of the 
INR263A/K264A mutant virus in shSCR cells; p = 0.5836, Mann-Whitney test. 
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